Pancreatic Cancer Research

ResearcherLund UniversityActive in the last 2 years

Monika Posaric Bauden

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6088-9268; OpenAlex author ID A5088609574, A5158651699. Sources: OpenAlex.

Their work

Papers
30 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 3 papers · 2017: 5 papers · 2018: 6 papers · 2019: 5 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 30

  1. Transcriptomic profiling reveals autophagy-associated programs and prognostic biomarkers in anoikis-resistant pancreatic cancer cells. First author DOI 10.1186/s12885-026-17107-7↗
  2. A Tissue-based Biomarker Risk Score for Predicting Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/cdp.10496↗
  3. Anoikis-related genes linked with patient outcome in pancreatic cancer. Co-author DOI 10.1016/j.gene.2024.148868↗
  4. L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer. First author DOI 10.1177/10732748241251583↗
  5. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. First author DOI 10.1186/s12967-020-02254-7↗
  6. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. Co-author DOI 10.1016/j.ebiom.2019.04.008↗
  7. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Co-author DOI 10.1016/j.trsl.2019.06.003↗
  8. The Role of PEDF in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13473↗
  9. The Hippo Signaling Pathway in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13474↗
  10. Is immunotherapy the holy grail for pancreatic cancer? Co-author DOI 10.2217/imt-2019-0164↗
  11. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm. Co-author DOI 10.1080/00365521.2018.1532020↗
  12. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-5013-2↗
  13. Targeting dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-018-0585-0↗
  14. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23929↗
  15. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment. Co-author DOI 10.18632/oncotarget.24019↗
  16. Centrosomal Abnormalities in Pancreatic Cancer: Molecular Mechanisms and Clinical Implications. Co-author DOI 10.21873/anticanres.12345↗
  17. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. First author DOI 10.1002/bjs.10471↗
  18. Characterization of histone-related chemical modifications in formalin-fixed paraffin-embedded and fresh-frozen human pancreatic cancer xenografts using LC-MS/… Co-author DOI 10.1038/labinvest.2016.134↗
  19. Pancreatic cancer stroma: controversies and current insights. Co-author DOI 10.1080/00365521.2017.1293726↗
  20. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/00365521.2017.1301989↗
  21. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-017-3834-z↗
  22. Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter? First author DOI 10.21873/anticanres.10981↗
  23. Pancreatic cancer: yesterday, today and tomorrow. Co-author DOI 10.2217/fon-2016-0010↗
  24. Immune checkpoint therapy for pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i43.9457↗
  25. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. Co-author DOI 10.1007/s00432-014-1817-x↗
  26. Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy? First author DOI 10.1007/s13277-015-3479-y↗
  27. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Co-author DOI 10.1186/s13148-015-0139-4↗
  28. Analysis of MUC4 expression in human pancreatic cancer xenografts in immunodeficient mice. First author PMID 25075011↗
  29. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. Co-author PMID 25275019↗
  30. Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. Co-author DOI 10.3109/00365521.2013.832368↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roland E. Andersson · 30 shared papers, 2013–2026 · strength 3.46
  2. Daniel Ansari · 30 shared papers, 2013–2026 · strength 3.46
  3. György Marko‐Varga · 8 shared papers, 2015–2020 · strength 0.65
  4. Ragnar Norrsell · 2 shared papers, 2024–2025 · strength 0.59
  5. Dingyuan Hu · 6 shared papers, 2018–2020 · strength 0.55
  6. Qimin Zhou · 6 shared papers, 2018–2020 · strength 0.55
  7. Lizhi Lin · 2 shared papers, 2024–2025 · strength 0.51
  8. Lizhi Lin · 1 shared paper, 2026 · strength 0.43
  9. Bodil Andersson · 5 shared papers, 2015–2018 · strength 0.34
  10. Daniel Kříž · 1 shared paper, 2025 · strength 0.28
  11. Xiangyang Xue · 1 shared paper, 2024 · strength 0.23
  12. Bobby Tingstedt · 2 shared papers, 2016–2018 · strength 0.15
  13. Stefan Holdenrieder · 2 shared papers, 2016 · strength 0.15
  14. Helmut Frieß · 1 shared paper, 2018 · strength 0.11
  15. Chinmay Gundewar · 2 shared papers, 2013–2014 · strength 0.10
  16. Pascal Syren · 1 shared paper, 2017 · strength 0.10
  17. Linus Aronsson · 1 shared paper, 2018 · strength 0.10
  18. Anton Deicher · 1 shared paper, 2018 · strength 0.10
  19. Carlos Urey · 2 shared papers, 2013–2014 · strength 0.09
  20. Mengtao Zhou · 1 shared paper, 2019 · strength 0.08
  21. María José García Cebrián · 1 shared paper, 2016 · strength 0.08
  22. Marie Sahlin · 1 shared paper, 2015 · strength 0.07
  23. Henrik Johansson · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.